Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor

Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa

S. Sheth, D. Dimichele, M. Lee, Jacqueline M. Lamour, J. Quaegebeur, Daphne T. Hsu, L. Addonizio, S. Piomelli

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Four years prior to transplantation, a 14-year-old boy with severe haemophilia A and a high-responding factor VIII (FVIII) inhibitor developed an anteroseptal myocardial infarct while receiving high doses of an activated prothrombin complex concentrate (PCC). Cardiac transplantation was required for survival because of the ensuing cardiomyopathy. At surgery, the patient's inhibitor titre was 1.8 Bethesda units (BU). High-dose bolus therapy, followed by a continuous infusion of FVIII provided excellent operative and initial postoperative haemostasis without additional blood-product support. Once anamnaesis developed on day 6 postoperatively, recombinant factor VIIa (rFVIIa) therapy was initiated. Haemostasis remained excellent, except for the transient increase in chest-tube bleeding that was noted on day 7. ε-aminocaproic acid was added and haemostasis was re-established. On day 15, rFVIIa was replaced with alternate day infusions of prothrombin complex concentrates (PCCs). On day 21 following the transplant, the patient was discharged, remaining on daily FVIII immune tolerance and thrice-weekly PCC prophylaxis. He remains well 24 months after transplant with an inhibitor titre of 39 BU. This paper describes the second case of cardiac transplantation complicated by haemophilia and an inhibitor, and discusses preoperative planning and operative and postsurgical haemostasis management.

Original languageEnglish (US)
Pages (from-to)227-232
Number of pages6
JournalHaemophilia
Volume7
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Factor VIII
Hemostasis
Transplants
Hemophilia A
Heart Transplantation
Aminocaproic Acid
Chest Tubes
Immune Tolerance
Cardiomyopathies
Transplantation
Myocardial Infarction
Hemorrhage
Survival
recombinant FVIIa
Therapeutics
prothrombin complex concentrates

Keywords

  • Haemophilia
  • Heart transplant
  • Inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor : Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. / Sheth, S.; Dimichele, D.; Lee, M.; Lamour, Jacqueline M.; Quaegebeur, J.; Hsu, Daphne T.; Addonizio, L.; Piomelli, S.

In: Haemophilia, Vol. 7, No. 2, 2001, p. 227-232.

Research output: Contribution to journalArticle

@article{85a869358f1a47248c236567988c4819,
title = "Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa",
abstract = "Four years prior to transplantation, a 14-year-old boy with severe haemophilia A and a high-responding factor VIII (FVIII) inhibitor developed an anteroseptal myocardial infarct while receiving high doses of an activated prothrombin complex concentrate (PCC). Cardiac transplantation was required for survival because of the ensuing cardiomyopathy. At surgery, the patient's inhibitor titre was 1.8 Bethesda units (BU). High-dose bolus therapy, followed by a continuous infusion of FVIII provided excellent operative and initial postoperative haemostasis without additional blood-product support. Once anamnaesis developed on day 6 postoperatively, recombinant factor VIIa (rFVIIa) therapy was initiated. Haemostasis remained excellent, except for the transient increase in chest-tube bleeding that was noted on day 7. ε-aminocaproic acid was added and haemostasis was re-established. On day 15, rFVIIa was replaced with alternate day infusions of prothrombin complex concentrates (PCCs). On day 21 following the transplant, the patient was discharged, remaining on daily FVIII immune tolerance and thrice-weekly PCC prophylaxis. He remains well 24 months after transplant with an inhibitor titre of 39 BU. This paper describes the second case of cardiac transplantation complicated by haemophilia and an inhibitor, and discusses preoperative planning and operative and postsurgical haemostasis management.",
keywords = "Haemophilia, Heart transplant, Inhibitor",
author = "S. Sheth and D. Dimichele and M. Lee and Lamour, {Jacqueline M.} and J. Quaegebeur and Hsu, {Daphne T.} and L. Addonizio and S. Piomelli",
year = "2001",
doi = "10.1046/j.1365-2516.2001.00483.x",
language = "English (US)",
volume = "7",
pages = "227--232",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor

T2 - Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa

AU - Sheth, S.

AU - Dimichele, D.

AU - Lee, M.

AU - Lamour, Jacqueline M.

AU - Quaegebeur, J.

AU - Hsu, Daphne T.

AU - Addonizio, L.

AU - Piomelli, S.

PY - 2001

Y1 - 2001

N2 - Four years prior to transplantation, a 14-year-old boy with severe haemophilia A and a high-responding factor VIII (FVIII) inhibitor developed an anteroseptal myocardial infarct while receiving high doses of an activated prothrombin complex concentrate (PCC). Cardiac transplantation was required for survival because of the ensuing cardiomyopathy. At surgery, the patient's inhibitor titre was 1.8 Bethesda units (BU). High-dose bolus therapy, followed by a continuous infusion of FVIII provided excellent operative and initial postoperative haemostasis without additional blood-product support. Once anamnaesis developed on day 6 postoperatively, recombinant factor VIIa (rFVIIa) therapy was initiated. Haemostasis remained excellent, except for the transient increase in chest-tube bleeding that was noted on day 7. ε-aminocaproic acid was added and haemostasis was re-established. On day 15, rFVIIa was replaced with alternate day infusions of prothrombin complex concentrates (PCCs). On day 21 following the transplant, the patient was discharged, remaining on daily FVIII immune tolerance and thrice-weekly PCC prophylaxis. He remains well 24 months after transplant with an inhibitor titre of 39 BU. This paper describes the second case of cardiac transplantation complicated by haemophilia and an inhibitor, and discusses preoperative planning and operative and postsurgical haemostasis management.

AB - Four years prior to transplantation, a 14-year-old boy with severe haemophilia A and a high-responding factor VIII (FVIII) inhibitor developed an anteroseptal myocardial infarct while receiving high doses of an activated prothrombin complex concentrate (PCC). Cardiac transplantation was required for survival because of the ensuing cardiomyopathy. At surgery, the patient's inhibitor titre was 1.8 Bethesda units (BU). High-dose bolus therapy, followed by a continuous infusion of FVIII provided excellent operative and initial postoperative haemostasis without additional blood-product support. Once anamnaesis developed on day 6 postoperatively, recombinant factor VIIa (rFVIIa) therapy was initiated. Haemostasis remained excellent, except for the transient increase in chest-tube bleeding that was noted on day 7. ε-aminocaproic acid was added and haemostasis was re-established. On day 15, rFVIIa was replaced with alternate day infusions of prothrombin complex concentrates (PCCs). On day 21 following the transplant, the patient was discharged, remaining on daily FVIII immune tolerance and thrice-weekly PCC prophylaxis. He remains well 24 months after transplant with an inhibitor titre of 39 BU. This paper describes the second case of cardiac transplantation complicated by haemophilia and an inhibitor, and discusses preoperative planning and operative and postsurgical haemostasis management.

KW - Haemophilia

KW - Heart transplant

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0035085485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035085485&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2516.2001.00483.x

DO - 10.1046/j.1365-2516.2001.00483.x

M3 - Article

VL - 7

SP - 227

EP - 232

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -